CA2602562C - Modulation of telomere length in telomerase positive cells and cancer therapy - Google Patents

Modulation of telomere length in telomerase positive cells and cancer therapy Download PDF

Info

Publication number
CA2602562C
CA2602562C CA2602562A CA2602562A CA2602562C CA 2602562 C CA2602562 C CA 2602562C CA 2602562 A CA2602562 A CA 2602562A CA 2602562 A CA2602562 A CA 2602562A CA 2602562 C CA2602562 C CA 2602562C
Authority
CA
Canada
Prior art keywords
cancer
cells
nucleoside analog
different type
telomerase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2602562A
Other languages
English (en)
French (fr)
Other versions
CA2602562A1 (en
Inventor
Igor E. Bondarev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALT solutions Inc
Original Assignee
ALT solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALT solutions Inc filed Critical ALT solutions Inc
Publication of CA2602562A1 publication Critical patent/CA2602562A1/en
Application granted granted Critical
Publication of CA2602562C publication Critical patent/CA2602562C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2602562A 2005-03-25 2006-03-27 Modulation of telomere length in telomerase positive cells and cancer therapy Expired - Fee Related CA2602562C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66510505P 2005-03-25 2005-03-25
US60/665,105 2005-03-25
PCT/US2006/011027 WO2006104975A2 (en) 2005-03-25 2006-03-27 Modulation of telomere length in telomerase positive cells and cancer therapy

Publications (2)

Publication Number Publication Date
CA2602562A1 CA2602562A1 (en) 2006-10-05
CA2602562C true CA2602562C (en) 2015-07-07

Family

ID=37053967

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2602562A Expired - Fee Related CA2602562C (en) 2005-03-25 2006-03-27 Modulation of telomere length in telomerase positive cells and cancer therapy

Country Status (6)

Country Link
US (5) US7741296B2 (https=)
EP (1) EP1868615A4 (https=)
JP (2) JP2008536822A (https=)
CN (2) CN104997783A (https=)
CA (1) CA2602562C (https=)
WO (1) WO2006104975A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050113324A1 (en) * 2003-01-15 2005-05-26 Bondarev Igor E. Modulation of line-1 reverse transcriptase
JP2008545658A (ja) * 2005-05-18 2008-12-18 アルト ソリューションズ インコーポレーテッド 癌の予防及び治療のための、癌細胞におけるテロメア長の薬理学的調節
WO2007106561A2 (en) * 2006-03-14 2007-09-20 Alt Solutions, Inc. Prevention and treatment of cancer and other diseases
EP3578563B1 (en) 2011-12-22 2021-04-14 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
CN102660650A (zh) * 2012-05-25 2012-09-12 云南路易斯中药现代化工程技术研究中心 一种实时定量pcr测量样品中染色体端粒平均长度的绝对值的试剂盒及应用
JP6359028B2 (ja) * 2012-11-30 2018-07-18 ジェロン・コーポレーションＧｅｒｏｎ Ｃｏｒｐｏｒａｔｉｏｎ テロメラーゼ阻害剤を用いて細胞増殖性障害を処置するための診断マーカー
US9795242B2 (en) 2013-02-14 2017-10-24 Cirkul, Inc. Additive delivery systems and containers
ES2748334T3 (es) 2014-11-21 2020-03-16 Cirkul Inc Sistemas de cartuchos de aditivos ajustables
US10888826B2 (en) 2014-11-21 2021-01-12 Cirkul, Inc. Adjustable additive cartridge systems and methods
EP3753563A1 (en) * 2019-06-20 2020-12-23 Helmholtz-Zentrum für Infektionsforschung GmbH Anti-herpesvirus guanosine analogue for the inhibition of basal autophagy
CN112168829B (zh) * 2020-09-24 2022-02-15 华南理工大学 抗病毒药物在制备治疗骨髓增生异常综合征药物中的应用及制得的骨髓增生异常综合征药物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585363A (en) * 1987-05-05 1996-12-17 City Of Hope Circumvention of human tumor drug resistance
US5166140A (en) * 1987-05-05 1992-11-24 City Of Hope Use of certain nucleoside analogs to attenuate cancer cell resistance to DNA damaging chemotherapy
US5489508A (en) * 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5654286A (en) * 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5981507A (en) * 1995-12-14 1999-11-09 Advanced Magnetics, Inc. Polymeric carriers linked to nucleotide analogues via a phosphoramide bond
GB9601544D0 (en) * 1996-01-26 1996-03-27 Smithkline Beecham Plc Pharmaceuticals
JP2003503319A (ja) * 1999-06-23 2003-01-28 ザ ユニバーシティ オブ バーモント アンド ステイト アグリカルチュラル カレッジ アンカップリングタンパク質発現を操作する方法および産物
US20050113324A1 (en) * 2003-01-15 2005-05-26 Bondarev Igor E. Modulation of line-1 reverse transcriptase

Also Published As

Publication number Publication date
US20160000937A1 (en) 2016-01-07
CN104997783A (zh) 2015-10-28
US20100227832A1 (en) 2010-09-09
US8097595B2 (en) 2012-01-17
JP2013224953A (ja) 2013-10-31
US7741296B2 (en) 2010-06-22
US20120107863A1 (en) 2012-05-03
US8580753B2 (en) 2013-11-12
US20140065072A1 (en) 2014-03-06
CA2602562A1 (en) 2006-10-05
WO2006104975A3 (en) 2007-12-27
JP2008536822A (ja) 2008-09-11
WO2006104975A2 (en) 2006-10-05
CN101193643A (zh) 2008-06-04
US20090023677A1 (en) 2009-01-22
EP1868615A4 (en) 2012-06-27
EP1868615A2 (en) 2007-12-26

Similar Documents

Publication Publication Date Title
US8097595B2 (en) Modulation of telomere length in telomerase positive cells and cancer therapy
US9078901B2 (en) Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer
De Bolle et al. Potent, selective and cell-mediated inhibition of human herpesvirus 6 at an early stage of viral replication by the non-nucleoside compound CMV423
Clercq Highly potent and selective inhibition of varicella‐zoster virus replication by bicyclic furo [2, 3‐d] pyrimidine nucleoside analogues
US20090203636A1 (en) Prevention and Treatment of Cancer and Other Diseases
Schneider et al. Biphasic cytotoxic mechanism of extracellular ATP on U-937 human histiocytic leukemia cells: involvement of adenosine generation
Neyts et al. Intracellular metabolism of the N7-substituted acyclic nucleoside analog 2-amino-7-(1, 3-dihydroxy-2-propoxymethyl) purine, a potent inhibitor of herpesvirus replication
Goldberg et al. On the action of fluorouracil on leukemia cells
US11884730B2 (en) Methods of sensitizing cancer to immunotherapy
Liekens et al. The nucleotide analog cidofovir suppresses basic fibroblast growth factor (FGF2) expression and signaling and induces apoptosis in FGF2-overexpressing endothelial cells
US8501734B2 (en) Medical intervention in haematological cancers
CN101443021A (zh) 癌和其他疾病的预防和治疗
Iwazaki et al. 2′-Deoxycytidine decreases the anti-tumor effects of 5-fluorouracil on mouse myeloma cells
O’Konek et al. Alteration of the carbohydrate for deoxyguanosine analogs markedly changes DNA replication fidelity, cell cycle progression and cytotoxicity
De Clercq Nucleoside Analogues (BCNAS)
Garrett et al. erythroleukemia cells
Levkoff Inhibitory effect of bromodeoxyuridine on long-term cell proliferation

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170327